Skip to Main Content

In the face of growing criticism over its efforts to place a value on new medicines, the Institute for Clinical and Economic Review is trying to strike back. Recently, the nonprofit took a conciliatory approach by soliciting suggestions for improving its methods, but this week it became more aggressive by trying to dispel what it calls the “myths” about its operations and motives.

The controversial organization released a manifesto on Tuesday that attempts to rebut its many critics, who have chastised ICER for purportedly having cozy relationships with insurers; failing to sufficiently take into account the views of patients; and not providing enough time for drug makers to respond to assessments, among other things.


“Unfortunately, some recent criticism has been fueled by a lack of knowledge about ICER, or even purposeful misinformation by a few vocal critics, who oppose a move toward pricing that is better aligned with the added value a drug, device, or treatment provides to patients,” the nonprofit wrote in explaining the reasons for issuing its paper.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!